STADA Arzneimittel Aktiengesellschaft
STADA Arzneimittel Aktiengesellschaft, commonly known as STADA, is a prominent player in the global pharmaceutical industry, headquartered in Bad Vilbel, Germany. Founded in 1895, the company has established a strong presence in Europe and beyond, focusing on the development, manufacturing, and marketing of generic and over-the-counter (OTC) products. STADA's core offerings include a diverse range of pharmaceuticals, particularly in the fields of pain management, dermatology, and respiratory health. The company is recognised for its commitment to quality and innovation, which has positioned it as a trusted provider in the healthcare sector. With a robust portfolio and a strategic focus on expanding its market reach, STADA continues to achieve significant milestones, reinforcing its status as a leader in the pharmaceutical landscape.
DitchCarbon Score
How does STADA Arzneimittel Aktiengesellschaft's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
STADA Arzneimittel Aktiengesellschaft's score of 58 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
STADA Arzneimittel Aktiengesellschaft's reported carbon emissions
In 2023, STADA Arzneimittel Aktiengesellschaft reported total greenhouse gas emissions of approximately 81827800 kg CO2e, which includes 40104500 kg CO2e from Scope 1 and 41723300 kg CO2e from Scope 2 emissions. The company has also disclosed significant Scope 3 emissions, amounting to about 672806000 kg CO2e, primarily from purchased goods and services. STADA has set ambitious climate commitments, aiming to reduce its absolute greenhouse gas emissions (Scope 1 and 2) by 42% by 2030, using 2020 figures as a baseline. This target aligns with the 1.5°C global warming target. Additionally, the company has achieved a notable reduction of 33.7% in both Scope 1 and Scope 2 emissions over the past four years, demonstrating its commitment to sustainability and climate action. As a key player in the pharmaceuticals, biotechnology, and life sciences sector, STADA is actively working towards reducing its carbon footprint and enhancing its environmental performance.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 38,202,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 93,417,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
STADA Arzneimittel Aktiengesellschaft is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
